Market Overview

According to fortune business insights, the global inflammatory bowel disease treatment market size was valued at USD 29.57 billion in 2025. The market is projected to grow from USD 31.24 billion in 2026 to USD 41.64 billion by 2034, exhibiting a CAGR of 3.66% during the forecast period. North America dominated the inflammatory bowel disease treatment market with a market share of 41.01% in 2025.

The analysis shows that the increasing prevalence of ulcerative colitis and Crohn's disease, combined with a greater emphasis on early diagnosis and adequate reimbursement in developed nations, is driving market growth. This has led to a rising number of patients seeking treatment and an increased demand for therapeutics such as TNF inhibitors, IL inhibitors, and JAK inhibitors. The COVID-19 pandemic caused a temporary slowdown due to reduced patient visits, but the market has since recovered and is projected to grow steadily as key players focus on gaining regulatory approvals for new treatments.

Major Players Profiled in the Market Report:

• AbbVie Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Tokyo)
• UCB S.A. (Belgium)
• Bausch Health Companies Inc. (Canada)
• Bristol-Myers Squibb Company (U.S.)
• Pfizer Inc. (U.S.)
• CELLTRION INC. (South Korea)
• Johnson & Johnson Services, Inc. (U.S.)

Segments

Increasing Prevalence of Crohn’s Disease to Dominate Segment Growth

Based on disease indication, the market is segmented into Crohn's disease and ulcerative colitis. The Crohn’s disease segment is expected to hold the largest market share (63.78% in 2026), driven by its increasing prevalence and the rising number of patients undergoing treatment globally.

Injectables Segment to Hold Largest Market Share due to Rapid Adoption of Biologics

By route of administration, the market is divided into oral and injectables. The injectables segment is anticipated to hold the largest market share (77.58% in 2026) due to the increasing adoption and regulatory approval of biologic treatments, which are administered via injection.

TNF Inhibitors Segment Dominated Market due to Rise in their Development by Key Market Players

Based on drug class, the market is categorized into IL Inhibitors, TNF inhibitors, anti-integrin, JAK Inhibitors, and others. The TNF inhibitors segment is set to dominate with a 58.77% market share in 2026, owing to its effectiveness and the strong development pipeline from key pharmaceutical companies.

Hospital Pharmacy Segment Held Significant Market Share due to Reimbursement Policies